Lymphatic filariasis

Operational research to develop an M&E strategy to guide triple drug stopping decisions for lymphatic filariasis in Kenya

What is the indicator(s) and accompanying M&E strategy that enables country programs to determine when the risk of ongoing transmission of LF has been reduced so that IDA can be stopped with little risk of resurgence of transmission?

Countries: Kenya

Lymphatic Filariasis Positive-Case Follow-up After TAS 2 in Haiti

To identify the sampling strategy for positive case follow-up after TAS 2 and TAS 3 that optimizes the chances of correctly identifying evidence of ongoing transmission, while saving program resources.

Countries: Haiti

Improving Access to Mass Drug Administration for Lymphatic Filariasis Elimination using a Participatory Approach among Communities of Coastal Kenya

To assess the socio-economic factors contributing to low access to MDA, to identify the existing health services opportunities and other outlets specific to various socio-economic groups that could be used for improving access to MDA, and to develop feasible field-applicable strategies that can be used to reach groups with consistently low access to MDA.

Countries: Kenya

Development of Tools to Re-Orient Social Mobilization Strategies to Close the MDA Coverage-Compliance Gap

To improve compliance and reduce the coverage-compliance gap in mass drug administration through enhanced and tailored social mobilization.

Countries: Indonesia

Operational research to develop an M&E strategy to guide triple drug stopping decisions for lymphatic filariasis in Samoa

What is the indicator(s) and accompanying M&E strategy that enables country programs to determine when the risk of ongoing transmission of LF has been reduced so that IDA can be stopped with little risk of resurgence of transmission?

Countries: Samoa

Development of a geostatistical mapping tool to improve decision-making for Loa loa and LF

Can serological markers for NTDs (particularly Loa loa and Lymphatic filariasis) be incorporated into geostatistical maps and used to guide program decisions around treatment and surveillance?

District Mapping Onchocerciasis and Lymphatic Filariasis in Ethiopia

To assess the programmatic feasibility of and determine the most appropriate age group and sampling strategy for an oncho mapping survey for ivermectin-naïve areas

Countries: Ethiopia

District Mapping Onchocerciasis and Lymphatic Filariasis in Kenya

To assess the programmatic feasibility of and determine the most appropriate age group and sample strategy for an onchocerciasis mapping survey for ivermectin-naïve areas.

Countries: Kenya

Lymphatic filariasis positive-case follow-up after TAS 2 or TAS 3 in Philippines

To identify the sampling strategy for positive case follow-up after TAS 2 and TAS 3 that optimizes the chances of correctly identifying evidence of ongoing transmission, while saving program resources.

Countries: Philippines

District Elimination Mapping of Onchocerciasis in Burundi

To assess Onchocerciasis transmission in the districts previously called hypo-endemic or of unknown endemicity using a new more sensitive diagnostic and sampling strategy

Countries: Burundi

Pages